<?xml version='1.0' encoding='utf-8'?>
<document id="17575239"><sentence text="Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes."><entity charOffset="27-36" id="DDI-PubMed.17575239.s1.e0" text="gefitinib" /><entity charOffset="41-50" id="DDI-PubMed.17575239.s1.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.17575239.s1.e0" e2="DDI-PubMed.17575239.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17575239.s1.e0" e2="DDI-PubMed.17575239.s1.e1" /></sentence><sentence text="To examine the enzyme kinetics of gefitinib and erlotinib metabolism by individual cytochrome P450 (CYP) enzymes, and to compare their effects on CYP3A activity, with the aim to better understand mechanisms underlying pharmacokinetic variability and clinical effects"><entity charOffset="34-43" id="DDI-PubMed.17575239.s2.e0" text="gefitinib" /><entity charOffset="48-57" id="DDI-PubMed.17575239.s2.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.17575239.s2.e0" e2="DDI-PubMed.17575239.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17575239.s2.e0" e2="DDI-PubMed.17575239.s2.e1" /></sentence><sentence text="" /><sentence text="Enzyme kinetics were examined by incubating gefitinib or erlotinib (1"><entity charOffset="44-53" id="DDI-PubMed.17575239.s4.e0" text="gefitinib" /><entity charOffset="57-66" id="DDI-PubMed.17575239.s4.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.17575239.s4.e0" e2="DDI-PubMed.17575239.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17575239.s4.e0" e2="DDI-PubMed.17575239.s4.e1" /></sentence><sentence text="5-50 micromol/L) with recombinant human CYP3A4, CYP3A5, CYP2D6, CYP1A1, CYP1A2, and CYP1B1 (10-160 pmol/mL)" /><sentence text=" Their effects on CYP3A activity were examined by comparing midazolam metabolism in the presence and absence of gefitinib or erlotinib in human liver and intestinal microsomes"><entity charOffset="60-69" id="DDI-PubMed.17575239.s6.e0" text="midazolam" /><entity charOffset="112-121" id="DDI-PubMed.17575239.s6.e1" text="gefitinib" /><entity charOffset="125-134" id="DDI-PubMed.17575239.s6.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.17575239.s6.e0" e2="DDI-PubMed.17575239.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17575239.s6.e0" e2="DDI-PubMed.17575239.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17575239.s6.e0" e2="DDI-PubMed.17575239.s6.e2" /><pair ddi="false" e1="DDI-PubMed.17575239.s6.e1" e2="DDI-PubMed.17575239.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17575239.s6.e1" e2="DDI-PubMed.17575239.s6.e2" /></sentence><sentence text=" Parent compounds and metabolites were monitored by high-performance liquid chromatography with a photodiode detector or tandem mass spectrometer" /><sentence text="" /><sentence text="Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0" /><sentence text="41, 0" /><sentence text="39, and 0" /><sentence text="57 mL/min/nmol for gefitinib and 0"><entity charOffset="19-28" id="DDI-PubMed.17575239.s12.e0" text="gefitinib" /></sentence><sentence text="24, 0" /><sentence text="21, 0" /><sentence text="31 mL/min/nmol for erlotinib"><entity charOffset="19-28" id="DDI-PubMed.17575239.s15.e0" text="erlotinib" /></sentence><sentence text=" CYP2D6 was involved in gefitinib metabolism (Cl(max), 0"><entity charOffset="24-33" id="DDI-PubMed.17575239.s16.e0" text="gefitinib" /></sentence><sentence text="63 mL/min/nmol) to a large extent, whereas CYP1A2 was considerably involved in erlotinib metabolism (Cl(max), 0"><entity charOffset="79-88" id="DDI-PubMed.17575239.s17.e0" text="erlotinib" /></sentence><sentence text="15 mL/min/nmol)" /><sentence text=" Both drugs stimulated CYP3A-mediated midazolam disappearance and 1-hydroxymidazolam formation in liver and intestinal microsomes"><entity charOffset="66-84" id="DDI-PubMed.17575239.s19.e0" text="1-hydroxymidazolam" /></sentence><sentence text="" /><sentence text="Gefitinib is more susceptible to CYP3A-mediated metabolism than erlotinib, which may contribute to the higher apparent oral clearance observed for gefitinib"><entity charOffset="0-9" id="DDI-PubMed.17575239.s21.e0" text="Gefitinib" /><entity charOffset="64-73" id="DDI-PubMed.17575239.s21.e1" text="erlotinib" /><entity charOffset="147-156" id="DDI-PubMed.17575239.s21.e2" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.17575239.s21.e0" e2="DDI-PubMed.17575239.s21.e0" /><pair ddi="false" e1="DDI-PubMed.17575239.s21.e0" e2="DDI-PubMed.17575239.s21.e1" /><pair ddi="false" e1="DDI-PubMed.17575239.s21.e0" e2="DDI-PubMed.17575239.s21.e2" /><pair ddi="false" e1="DDI-PubMed.17575239.s21.e1" e2="DDI-PubMed.17575239.s21.e1" /><pair ddi="false" e1="DDI-PubMed.17575239.s21.e1" e2="DDI-PubMed.17575239.s21.e2" /></sentence><sentence text=" Metabolism by hepatic and extrahepatic CYP1A may represent a determinant of pharmacokinetic variability and response for both drugs" /><sentence text=" The differential metabolizing enzyme profiles suggest that there may be differences in drug-drug interaction potential and that stimulation of CYP3A4 may likely play a role in drug interactions for erlotinib and gefitinib"><entity charOffset="199-208" id="DDI-PubMed.17575239.s23.e0" text="erlotinib" /><entity charOffset="213-222" id="DDI-PubMed.17575239.s23.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.17575239.s23.e0" e2="DDI-PubMed.17575239.s23.e0" /><pair ddi="false" e1="DDI-PubMed.17575239.s23.e0" e2="DDI-PubMed.17575239.s23.e1" /></sentence><sentence text="" /></document>